Investor Relations

Print page     Email page

Myrexis, Inc., headquartered in New York, New York, is in the process of evaluating strategic alternatives, including focusing on identifying, evaluating and making financial investments life sciences assets. In February 2012, the Company announced that it was shifting its strategic direction and suspended development activities of all its preclinical and clinical development programs in oncology and autoimmune diseases.

Recent Releases Jan 23, 2013 Myrexis, Inc. Announces the Cancellation of Its Upcoming Shareholder Meeting Nov 9, 2012 Myrexis, Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution View all releases »

Stock Chart 3 Mo.   6 Mo.   1 Yr. Stock Quote Myrexis, Inc. Price: 0.08 Change: 0.01 Day High: 0.08 Day Low: 0.07 Volume: 71,400 Delayed at least 20 minutes. Provided by eSignal.